Objective: Proton beam re-irradiation (PBI) remains an effective and globe-preserving alternative to enucleation in the treatment of local recurrence in uveal melanoma. The study aimed to assess visual outcomes and prognostic factors in visual acuity (VA) after proton beam salvage therapy.
Design: Retrospective study.
Subjects: A retrospective study evaluated patients with recurrent uveal melanoma treated with PBI from 1984 through 2019 at a single academic tertiary center.
Methods: Patient and tumor characteristics were collected from the medical record, as well as best visual acuity (BVA) and ocular outcomes after treatment of recurrent uveal melanoma with PBI.
Main Outcome Measures: The primary outcome of the study was the BVA of patients after PBI for recurrent uveal melanoma. Additional outcome measures included enucleation rate of patients after salvage PBI and analysis of tumor and patient characteristics in the prognostication of VA.
Results: The study comprised 67 patients who received PBI for recurrent uveal melanoma. The median age at recurrence was 67.6 years (range, 31.6-91.0 years), and median follow-up from the time of recurrence to last examination was 4.4 years (range, 0.23-17.1 years). The median final BVA was hand motions (range, 20/20 to no light perception) and 6 (9.1%) patients maintained a Snellen VA 20/40 or better. The 5-year probability of VA retention of 20/200 or better was 19%. In a multivariable Cox model, VA at tumor recurrence of worse than 20/40 was found to be significantly associated with a VA of 20/200 or worse after retreatment with PBI. Twelve (18%) patients underwent enucleation after retreatment with PBI.
Conclusions: Proton beam irradiation for the treatment of recurrent uveal melanoma allows for ocular preservation and functional vision in select patients.
Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oret.2024.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ruthenium-106 brachytherapy and central uveal melanoma.
Int Ophthalmol
January 2025
Department of Ophthalmology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Purpose: Uveal melanoma (UM) is the most common primary ocular malignancy. The size and location of the tumor are decisive for brachytherapy with the β-emitting ruthenium-106 (Ru-106) plaque. The treatment of juxtapapillary and juxtafoveolar UM may be challenging because of the proximity or involvement of the macula and optic nerve and high recurrence rates.
View Article and Find Full Text PDFBlack posterior vitreous detachment: A 10-year historical cohort of pigmented uveal tumors.
Heliyon
January 2025
Faculty of Medical and Health Sciences, Tel Aviv University, Israel.
Objective: Pigmentary posterior vitreous detachment (PVD), referred to as "black PVD," is a rare entity describing PVD along with pigment dispersion in the vitreous. There are a few case reports describing pigmentary PVD, yet the association between pigmentary PVD and uveal and optic disc tumors was not described before. The aim of this study was to report the clinical features of patients with pigmentary PVD associated with these tumors.
View Article and Find Full Text PDFMicrodissection of Distinct Morphological Regions Within Uveal Melanomas Identifies Novel Drug Targets.
Cancers (Basel)
December 2024
SydPath, St Vincent's Hospital Sydney, Darlinghurst, NSW 2010, Australia.
: Uveal melanomas (UMs) are rare but often deadly malignancies that urgently require viable treatment options. UMs often exhibit tumour heterogeneity, with macroscopic and microscopic differences in morphology between different regions of the same tumour. However, to date, the clinical significance of this and how it may help guide personalised therapy have not been realised.
View Article and Find Full Text PDFLeopard spot retinopathy represents the initial sign of rhegmatogenous retinal detachment in children: a report of two cases.
BMC Ophthalmol
December 2024
Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei Province, China.
Background: Leopard spots can appear in a variety of diseases; however, they are extremely rare in children with rhegmatogenous retinal detachment. This study presents two such rare cases in which leopard spot retinopathy was the initial manifestation of rhegmatogenous retinal detachment.
Case Presentation: Case 1 involved a 4-year-old boy had previously been diagnosed with left eye uveitis and received systemic steroid therapy at a local hospital, but symptoms persisted.
Clinical Features and Initial Management Outcomes of Uveal Melanomas in a Single Tertiary Center in Egypt.
Ocul Oncol Pathol
December 2024
Cairo University Ocular Oncology Service, Department of Ophthalmology, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt.
Article Synopsis
- The study focuses on the demographic, clinical, and management outcomes of patients with uveal melanoma at a tertiary center in Egypt over five years.
- A total of 93 patients were treated, with most tumors being choroidal, and common treatments included brachytherapy and gamma knife radiosurgery, leading to a successful globe salvage rate of 84.62%.
- The conclusion emphasizes the importance of timely referrals and proper assessments to improve treatment success and highlights the need for advanced tumor patients to consider enucleation to lower the risk of metastasis and mortality.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!